MAPK8 and urinary bladder carcinoma: To further confirm whether JNK and p38 activation contributed to vitamin K2-triggered apoptosis in human bladder cancer cells, SP600125 (a pharmacological inhibitor of JNK) and SB203580 (a pharmacological inhibitor of p38) were used.